Elevance Health reaffirms full-year 2026 earnings guidance at least $20.10 per share
The health insurer maintains its full-year financial outlook as executives prepare to meet with investors and analysts over the coming weeks.
Elevance Health, Inc. (ELV) announced Wednesday in a regulatory filing that company officers will reaffirm its full-year 2026 financial guidance during upcoming meetings with investors and analysts.
Key takeaways
- Full-year 2026 earnings guidance reaffirmed at least $20.10 per diluted share.
- Net unfavorable items included at approximately $6.90 per diluted share.
- Adjusted shareholders’ earnings expected to be at least $27.00 per diluted share.
- Benefit expense ratio guidance reaffirmed at 90.2% plus or minus 50 basis points.
Earnings and expense guidance details
The company said in a filing that its full-year 2026 shareholders’ earnings guidance remains at least $20.10 per diluted share. This figure includes approximately $6.90 per diluted share of net unfavorable items. Excluding these items, the company continues to expect adjusted shareholders’ earnings to be at least $27.00 per diluted share. The company noted that this excludes any other adjustment items beyond those reported in its second quarter 2026 earnings.
Benefit expense ratio
In addition to earnings guidance, company officers will reaffirm the full-year 2026 benefit expense ratio guidance during upcoming investor meetings. The ratio is expected to be 90.2% plus or minus 50 basis points, according to the regulatory filing.
Why it matters
The reaffirmation provides visibility into the company's financial expectations for the remainder of the year as management engages with capital markets participants. The guidance figures remain consistent with previously reported metrics from the second quarter, without incorporating any new adjustment items.
By the numbers
| Metric | Value | Source | |---|---|---|> | Shareholders earnings per share | At least $20.10 | Regulatory filing | | Net unfavorable items | Approximately $6.90 | Regulatory filing | | Adjusted earnings per share | At least $27.00 | Regulatory filing | | Benefit expense ratio | 90.2% plus or minus 50 basis points | Regulatory filing |
What happens next
Company officers will speak with investors and analysts over the next several weeks to discuss the reaffirmed financial outlook. The disclosures were furnished under Item 7.01 of Form 8-K as Regulation FD disclosure and are not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.